报价延迟最少15分钟:2025/11/07 13:27 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.685 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.45/0.54
|
|
企业价值
1.54B
|
| 资产负债 |
|
每股账面净值
4.21
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
277.25M
|
|
每股收益
3.08
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/07 13:27 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
